Dose‐dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats
Open Access
- 1 July 1998
- journal article
- Published by Wiley in Immunology
- Vol. 94 (3) , 431-437
- https://doi.org/10.1046/j.1365-2567.1998.00526.x
Abstract
Nasal administration of soluble antigens is an exciting means of specifically down‐regulating pathogenic T‐cell reactivities in autoimmune diseases. The mechanisms by which nasal administration of soluble antigens suppresses autoimmunity are poorly understood. To define further the principles of nasal tolerance induction, we studied the effects of nasal administration of myelin basic protein (MBP) on experimental autoimmune encephalomyelitis (EAE) in the Lewis rat. EAE is a CD4+ T‐cell‐mediated animal model for human multiple sclerosis. Nasal administration of guinea‐pig (gp)‐MBP at a dose as low as 30 μg/rat can completely prevent gp‐MBP‐induced EAE, whereas nasal administration of bovine (b)‐MBP is not effective even at a much higher dosage. Cellular immune responses, as reflected by T‐cell proliferation and interferon‐γ (IFN‐γ)‐ELISPOT, were suppressed in rats receiving the two different doses (30 and 600 μg/rat) of gp‐MBP, but not after administration of b‐MBP. Rats tolerized with both doses of gp‐MBP had also abrogated MBP‐induced IFN‐γ mRNA expression in popliteal and inguinal lymph node mononuclear cells compared with rats receiving phosphate‐buffered saline nasally. However, adoptive transfer revealed that only spleen mononuclear cells from rats pretreated with a low dose, but not from those pretreated with a high dose, of gp‐MBP transferred protection to actively induced EAE. Low‐dose (30 μg/rat) gp‐MBP‐tolerized rats also had high numbers of interleukin‐4 (IL‐4) mRNA‐expressing lymph node cells, while high‐dose (600 μg/rat) gp‐MBP‐tolerized rats had low numbers of IL‐4 mRNA‐expressing lymph node cells. Our data suggest an exquisite specificity of nasal tolerance. Dose‐dependent mechanisms also relate to nasal tolerance induction and protection against EAE in the Lewis rat.Keywords
This publication has 45 references indexed in Scilit:
- Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNAJournal of Neuroimmunology, 1997
- Regulation of T cell function in mucosal toleranceImmunology & Cell Biology, 1997
- IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune diseaseImmunology Today, 1996
- Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitopeClinical and Experimental Immunology, 1996
- Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic proteinNature, 1996
- Induction of Interferon-γ, Interleukin-4, and Transforming Growth Factor-β in Rats Orally Tolerized against Experimental Autoimmune Myasthenia GravisCellular Immunology, 1994
- Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of AutoantigensAnnual Review of Immunology, 1994
- Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain.The Journal of Experimental Medicine, 1992
- The role of nasopharyngeal lymphoid tissueImmunology Today, 1992
- Antigen-driven bystander suppression after oral administration of antigens.The Journal of Experimental Medicine, 1991